Andrea B. Apolo, MD, National Cancer Institute

Articles

Novel Therapy in Urothelial Carcinoma: An Evolving Treatment Landscape

May 18th 2023

Closing out their discussion on urothelial carcinoma, key opinion leaders share clinical pearls and excitement for the evolving treatment landscape.

Sequencing Later-Line Therapies for Metastatic Urothelial Carcinoma

May 18th 2023

A brief review of second-line and subsequent treatment strategies in metastatic urothelial carcinoma and novel therapies being explored in this space.

Metastatic Urothelial Carcinoma: Intensifying Maintenance Immunotherapy

May 11th 2023

Shared insight on clinical trial data behind the intensification of maintenance immunotherapy in patients with metastatic urothelial carcinoma.

Real-World Data With Avelumab Maintenance Therapy in Metastatic Urothelial Carcinoma

May 11th 2023

Centering discussion on several key clinical trials, expert panelists reflect on data behind maintenance avelumab in metastatic urothelial carcinoma.

Goals of Maintenance Therapy in Metastatic Urothelial Carcinoma

May 4th 2023

A panel of four key opinion leaders discuss the role of maintenance therapy in metastatic urothelial carcinoma and how its use has impacted the treatment landscape.

Metastatic Urothelial Carcinoma: Number of Frontline Chemotherapy Cycles

May 4th 2023

A brief review of the appropriate number of chemotherapy cycles to utilize in the setting of metastatic urothelial carcinoma.

First-Line Treatment Options for Patients With Metastatic Urothelial Carcinoma

April 27th 2023

Switching their focus to the metastatic urothelial carcinoma treatment landscape, panelists identify cornerstone frontline treatment options.

Novel Treatment Strategies in Muscle Invasive Bladder Cancer

April 27th 2023

A comprehensive review of novel treatment strategies in MIBC, including perioperative therapy, and respective ongoing clinical trials.

Clinical Trial Data With Perioperative Therapy in MIBC: Bladder BRIDGister

April 20th 2023

Expert panelists reflect on the molecular subtyping of patients to predict response to neoadjuvant therapy in Bladder BRIDGister.

Clinical Trial Data With Perioperative Therapy in MIBC: HCRN GU 16-257

April 20th 2023

Shared insight on the combination of gemcitabine, cisplatin, and nivolumab in patients with muscle-invasive bladder cancer in the HCRN GU 16-257 trial.

Clinical Trial Data With Perioperative Therapy in MIBC: The RETAIN BLADDER Study

April 13th 2023

Focused discussion on the RETAIN BLADDER study, which explored the option to avoid cystectomy in patients with good response to systemic therapy.

Muscle-Invasive Bladder Cancer: Role of Minimal Residual Disease in Adjuvant Therapy

April 13th 2023

Continuing their discussion on adjuvant therapy in in muscle-invasive bladder cancer, panelists identify the utility of minimal residual disease testing.

Adjuvant Treatment Approaches in Muscle-Invasive Bladder Cancer

April 6th 2023

Centering discussion on several clinical trials, key opinion leaders reflect on the role of adjuvant therapy in muscle-invasive bladder cancer.

Evolving Neoadjuvant Treatment Strategies in Muscle-Invasive Bladder Cancer

April 6th 2023

Expert perspectives on the evolving role of neoadjuvant therapy in muscle-invasive bladder cancer (MIBC) with considerations for mainstay regimens.

MIBC and mUC: Surgery, Systemic Therapy, and Bladder Preserving Treatments

March 30th 2023

Switching their focus to non-muscle-invasive bladder cancer (NMIBC), panelists identify the treatment armamentarium in this setting.

Novel Treatment Strategies in Non-Muscle Invasive Bladder Cancer

March 30th 2023

A bird’s eye view of treatment modalities in urothelial carcinoma covering systemic, surgical, and bladder preserving strategies.

How Many Lines of Therapy Are Patients Receiving for Urothelial Carcinoma?

March 23rd 2023

A brief review of sequencing patterns in urothelial carcinoma and the typical number of lines of therapy a patient may receive.

Overview of Practice Patterns in Urothelial Carcinoma

March 23rd 2023

A panel of four key opinion leaders share real-world urothelial carcinoma practice patterns at their respective institutions.

Dr. Apolo on Managing Toxicities of Checkpoint Inhibitors in Bladder Cancer

January 19th 2018

Andrea B. Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses managing immune-related toxicities from checkpoint inhibitors in patients with bladder cancer.

Dr. Apolo on Toxicity Challenges With Checkpoint Inhibitors in Bladder Cancer

December 21st 2017

Andrea B. Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses challenges with managing toxicities of checkpoint inhibitors for patients with bladder cancer.